Physician profile
Douglas Bretzing
NPI 1013365105
$2,409.46
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.97 · 2020: $465 · 2021: $456 · 2022: $617 · 2023: $535 · 2024: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $581.35 | 2020-2024 | Xarelto |
| Vifor Pharma, INC. | $254.55 | 2020-2024 | Veltassa |
| Inari Medical, INC. | $246.43 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.90 | 2022-2024 | Lifevest |
| Pfizer INC. | $188.19 | 2020-2024 | |
| Paratek Pharmaceuticals, INC. | $121.06 | 2020-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.02 | 2021-2023 | Jardiance |
| Rgh Enterprises LLC | $91.68 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $84.14 | 2019-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $71.33 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.04 | 2020-2023 | Xifaxan |
| Astellas Pharma US INC | $57.93 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $54.78 | 2022-2023 | Rebyota |
| Bioxcel Therapeutics, INC. | $42.78 | 2023 | Igalmi |
| Alexion Pharmaceuticals, INC. | $41.83 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.83 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Merck Sharp & Dohme LLC | $22.43 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Shionogi INC | $20.71 | 2022 | |
| Esperion Therapeutics, INC. | $20.15 | 2024 | Nexletol |
| Janssen Scientific Affairs, LLC | $17.65 | 2023 | Xarelto |
| Novo Nordisk INC | $14.22 | 2020 | |
| Pharmacosmos Therapeutics INC. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Bretzing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.